JSF Financial LLC Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

JSF Financial LLC acquired a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,866 shares of the pharmaceutical company’s stock, valued at approximately $751,000.

Other large investors also recently added to or reduced their stakes in the company. Czech National Bank increased its holdings in Vertex Pharmaceuticals by 6.2% in the 4th quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock worth $22,486,000 after acquiring an additional 3,260 shares during the last quarter. Whalen Wealth Management Inc. purchased a new position in Vertex Pharmaceuticals during the 3rd quarter valued at about $662,000. Concord Wealth Partners grew its holdings in Vertex Pharmaceuticals by 32.6% during the 4th quarter. Concord Wealth Partners now owns 3,508 shares of the pharmaceutical company’s stock valued at $1,413,000 after buying an additional 862 shares in the last quarter. Mizuho Securities USA LLC grew its holdings in Vertex Pharmaceuticals by 289.0% during the 3rd quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock valued at $35,994,000 after buying an additional 57,497 shares in the last quarter. Finally, Nordea Investment Management AB grew its holdings in Vertex Pharmaceuticals by 19.4% during the 4th quarter. Nordea Investment Management AB now owns 342,429 shares of the pharmaceutical company’s stock valued at $137,783,000 after buying an additional 55,739 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Up 0.1 %

Shares of NASDAQ:VRTX opened at $469.97 on Tuesday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The stock’s fifty day moving average price is $435.87 and its 200-day moving average price is $462.29.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. As a group, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.94 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on VRTX shares. Stifel Nicolaus lifted their price target on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a research report on Monday, December 16th. Scotiabank boosted their target price on Vertex Pharmaceuticals from $430.00 to $433.00 and gave the stock a “sector perform” rating in a research report on Friday, January 31st. Royal Bank of Canada boosted their target price on Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. HC Wainwright boosted their target price on Vertex Pharmaceuticals from $535.00 to $550.00 and gave the stock a “buy” rating in a research report on Friday, January 31st. Finally, StockNews.com downgraded Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 21st. One analyst has rated the stock with a sell rating, nine have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $502.58.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.